Switch theme
Sign up to access all valuation multiples
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
2016
1.2K+
LTM Revenue $243M
LTM EBITDA $53.3M
$273M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
VieMed has a last 12-month revenue (LTM) of $243M and a last 12-month EBITDA of $53.3M.
In the most recent fiscal year, VieMed achieved revenue of $224M and an EBITDA of $42.3M.
VieMed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See VieMed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $243M | XXX | $224M | XXX | XXX | XXX |
| Gross Profit | $141M | XXX | $133M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $53.3M | XXX | $42.3M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $19.7M | XXX | $16.0M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $13.1M | XXX | $11.3M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, VieMed's stock price is $7.
VieMed has current market cap of $277M, and EV of $273M.
See VieMed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $273M | $277M | XXX | XXX | XXX | XXX | $0.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, VieMed has market cap of $277M and EV of $273M.
VieMed's trades at 1.2x EV/Revenue multiple, and 6.5x EV/EBITDA.
Equity research analysts estimate VieMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
VieMed has a P/E ratio of 21.1x.
See valuation multiples for VieMed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $277M | XXX | $277M | XXX | XXX | XXX |
| EV (current) | $273M | XXX | $273M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 5.1x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBIT | 13.9x | XXX | 17.1x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.1x | XXX | 24.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 207.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVieMed's last 12 month revenue growth is 14%
VieMed's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
VieMed's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
VieMed's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for VieMed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
VieMed acquired XXX companies to date.
Last acquisition by VieMed was XXXXXXXX, XXXXX XXXXX XXXXXX . VieMed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was VieMed founded? | VieMed was founded in 2016. |
| Where is VieMed headquartered? | VieMed is headquartered in United States of America. |
| How many employees does VieMed have? | As of today, VieMed has 1.2K+ employees. |
| Who is the CEO of VieMed? | VieMed's CEO is Mr. Casey Hoyt. |
| Is VieMed publicy listed? | Yes, VieMed is a public company listed on NAS. |
| What is the stock symbol of VieMed? | VieMed trades under VMD ticker. |
| When did VieMed go public? | VieMed went public in 2018. |
| Who are competitors of VieMed? | Similar companies to VieMed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of VieMed? | VieMed's current market cap is $277M |
| What is the current revenue of VieMed? | VieMed's last 12 months revenue is $243M. |
| What is the current revenue growth of VieMed? | VieMed revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of VieMed? | Current revenue multiple of VieMed is 1.1x. |
| Is VieMed profitable? | Yes, VieMed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of VieMed? | VieMed's last 12 months EBITDA is $53.3M. |
| What is VieMed's EBITDA margin? | VieMed's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of VieMed? | Current EBITDA multiple of VieMed is 5.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
